Stereotactic Body Radiotherapy for the Treatment of OPD

Overview

HALT is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment.

HALT aims to recruit 110 patients with mutation positive advanced NSCLC with oligoprogressive disease (OPD) following initial response to a Tyrosine Kinase Inhibitor (TKI).

Full Title of Study: “Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 30, 2021

Detailed Description

Eligible patients will be randomised to receive either SBRT or no SBRT at a ratio of 2:1 (SBRT : no SBRT), with all patients continuing to receive background treatment with TKI therapy as clinically indicated and as per standard care. Patients randomised to receive SBRT will receive a dose and fractionation schedule dependent on OPD lesion site and proximity to critical normal tissues. All patients will be seen 8 weeks post randomisation, then 3 monthly in line with routine care.

HALT aims to assess whether in patients with mutation positive advanced NSCLC the use of SBRT to ≤ 3 sites of OPD with continuation of TKI improves progression-free survival (PFS) compared with continuation of TKI alone.

Interventions

  • Radiation: SBRT
    • SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
  • Drug: TKI
    • Continued background TKI alone

Arms, Groups and Cohorts

  • Experimental: SBRT and continued TKI therapy
    • Patients will continue to receive background TKI treatment as prior to trial entry. Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment. Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3.
  • Active Comparator: Continued TKI therapy alone
    • Continuation on the same background TKI treatment as prior to trial entry

Clinical Trial Outcome Measures

Primary Measures

  • Progression free survival
    • Time Frame: Time from randomisation to the first of one of the above events or death. Assessed 8 weeks post-randomisation and 3-monthly thereafter (up to 24 months)
    • The primary outcome measure is progression free survival defined as the time from randomisation to the first of one of the following events or death from any cause: Clinically symptomatic progression requiring palliative tumour-specific oncological intervention (e.g. change in systemic therapy or localised non-SBRT radiotherapy) as determined by the treating physician. New or existing intra-cranial lesions not amenable to radical surgery or Stereotactic radiosurgery (SRS). Development of new extra-cranial lesions or progression of existing extra-cranial lesions not meeting the criteria for SBRT treatment (e.g. size >5cm) Development of >3 new or progressing extra-cranial lesion at any one point in time (i.e. widespread progression)

Secondary Measures

  • Time to next line of systemic therapy or palliative care
    • Time Frame: Time from randomisation to change in therapy or referral to palliative care due to clinical progression as determined by the treating physician, or death. Assessed 3-monthly until progression and 6-monthly thereafter (up to 24 months).
  • Overall survival
    • Time Frame: Time from randomisation until death from any cause. Assessed up to 24 months.
  • Patterns of disease progression identified from CT scans to further document natural history of oncogene-addicted NSCLC
    • Time Frame: Assessed 3-monthly up to 24 months.
  • Radiotherapy toxicities (acute events)
    • Time Frame: Baseline, 8 weeks and 3-monthly intervals during follow-up (a minimum of 6 months).
    • Acute events are defined as ≤ 90 days post SBRT start date (applicable for each subsequent course of SBRT where relevant) assessed using CTCAE v4.0.
  • Radiotherapy toxicities (late events)
    • Time Frame: Baseline, 8 weeks and 3-monthly intervals during follow-up (a minimum of 6 months).
    • Late events are defined as > 90 days post SBRT start date (applicable for each subsequent course of SBRT where relevant) assessed using RTOG.
  • Quality of Life (EQ-5D-5L)
    • Time Frame: Baseline, 8 weeks and at the first 3 month visit.
    • Assessed using EQ-5D-5L
  • Quality of Life (EORTC QLQ-C30)
    • Time Frame: Baseline, 8 weeks and at the first 3 month visit.
    • Assessed using EORTC QLQ-C30
  • Measurement of resistant sub-clones in Circulating tumour DNA (ctDNA)
    • Time Frame: Baseline, 8 weeks post-randomisation and 3-monthly intervals during follow-up (up to 24 months).
  • Time to failure of next line treatment
    • Time Frame: Time from randomisation to disease progression on next line of active systemic therapy. Assessed up to 24 months.

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female, ≥ 16 years of age

2. Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with defined actionable mutation receiving targeted TKI therapy

3. Clinical and/or radiologically confirmed response to TKI therapy (assessed locally usually 2-3 months post commencing TKI)

4. Confirmed OPD defined as ≤ 3 extracranial sites of progressive disease. All sites must be visible, imaging defined targets and suitable for treatment with SBRT as determined by the virtual multi-disciplinary team (MDT) and in accordance with the HALT Radiotherapy planning and delivery guidance document.

5. Adequate baseline organ function to allow SBRT to all relevant targets

6. Predicted life expectancy ≥ 6 months

7. Karnofsky Index ≥ 60% and ECOG 0-2

8. Provision of written informed consent

Exclusion Criteria

1. > 3 extracranial sites of progressive disease

2. Progressing or newly diagnosed brain metastases not amenable to radical surgery or SRS. Treated brain metastases which have remained clinically and radiologically stable for ≥ 6 months are permissible.

3. Prior radiotherapy near the oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in section 4.1 of this document and will be determined by the HALT virtual MDT

4. Co-morbidities considered clinically precluding the safe use of SBRT (as detailed in the HALT radiotherapy planning and delivery guidelines).

5. Any psychological, sociological or geographical issue potentially hampering compliance with the study

6. Pregnancy

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institute of Cancer Research, United Kingdom
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fiona McDonald, MD, Principal Investigator, Royal Marsden NHS Foundation Trust
  • Overall Contact(s)
    • HALT Trial Manager, +442087224554, halt-icrctsu@icr.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.